IP Library Granted Patent US 8,003,673
Granted Patent B2
US 8,003,673 · App. 11/916,089 · Granted Aug 23, 2011

Daptomycin for the treatment of biofilm and catheter salvage

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,003,673
App. No.
11/916,089
Granted
Aug 23, 2011
Kind
B2
Abstract

Daptomycin can be used for biofilm treatment (particularly central venous catheter salvage for S. epidermidis infected catheters). Catheter salvage with daptomycin shows rapid cidality, activity against stationary phase bacteria, and penetration and activity in biofilms. The present inventions provide formulations, methods, and articles of manufacture useful for biofilm treatment or catheter salvage involving daptomycin. Particular formulations include daptomycin in lactated Ringer's solution having a rapid kill curve against the bacteria of the biofilm.

Claims (20)

1. A method for treating a biofilm, comprising providing a solution of daptomycin in a lactated Ringer's solution to a biofilm.

2. The method of claim 1 , wherein the biofilm is treated with the solution at least 30 minutes.

3. The method of claim 1 , further comprising applying the solution to the biofilm until the biofilm is reduced.

4. The method of claim 3 , wherein the biofilm is reduced and does not reoccur.

5. The method of claim 1 , wherein the solution is applied to the biofilm for about 30 minutes.

6. The method of claim 1 , wherein the solution is administered twice per day.

7. The method of claim 1 , wherein the solution is administered at least four times per day.

8. The method of claim 1 , wherein the concentration of daptomycin in the solution is at least 1 mg/mL.

9. The method of claim 1 , wherein the concentration of daptomycin in the solution is at least 5 mg/mL.

10. A method of treating or preventing a biofilm, the method comprising exposing a surface of a device to a solution comprising daptomycin and calcium.

11. The method of claim 10 , where the surface forms a portion of a catheter.

12. The method of claim 10 , where the surface is an inner luminal surface of a catheter, and the surface is exposed to the solution by catheter lock therapy.

13. The method of claim 10 , where the solution comprises about 5 mg/mL daptomycin and a physiological concentration of calcium.

14. The method of claim 12 , where the catheter lock therapy comprises exposing a surface of the catheter to the solution for about 18 hours.

15. The method of claim 10 , where the solution comprises daptomycin and lactated Ringer's solution.

16. The method of claim 11 , further comprising performing a heparin flush of the catheter.

17. The method of claim 11 , where the surface is exposed to the solution for at least about 30 minutes and the solution comprises about 5 mg/mL of daptomycin.

18. The method of claim 11 , where the catheter is a central venous catheter.

19. The method of claim 10 , where the method is a method of treating a biofilm in a catheter, the surface is an inner luminal surface of the catheter, and the solution comprises about 5 mg/mL daptomycin in lactated Ringer's solution.

20. A kit for the treatment of biofilm in a catheter comprising lactated Ringer's solution having daptomycin in an amount sufficient to treat the biofilm.

Assignments (6)
CHANGE OF ADDRESS Recorded Sep 14, 2016
From: CUBIST PHARMACEUTICALS LLC
To: CUBIST PHARMACEUTICALS LLC
Reel/Frame 040026/0743 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE PREVIOUSLY RECORDED AT REEL: 036308 FRAME: 0207. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST. Recorded Aug 14, 2015
From: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
To: CUBIST PHARMACEUTICALS, INC.; ADOLOR CORPORATION; CALIXA THERAPEUTICS, INC.
Reel/Frame 036355/0184 →
SECURITY INTEREST Recorded Aug 12, 2015
From: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
To: CUBIST PHARMACEUTICALS, INC.; ADOLOR CORPORATION; CALIXA THERAPEUTICS, INC.
Reel/Frame 036308/0207 →
CHANGE OF NAME Recorded Aug 5, 2015
From: CUBIST PHARMACEUTICALS, INC.
To: CUBIST PHARMACEUTICALS LLC
Reel/Frame 036283/0189 →
SECURITY AGREEMENT Recorded Nov 20, 2012
From: CUBIST PHARMACEUTICALS, INC.; ADOLOR CORPORATION; CALIXA THERAPEUTICS, INC.; CUBIST PHARMACEUTICALS HOLDINGS, INC.; CUBIST PHARMACEUTICALS U.S.
To: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
Reel/Frame 029339/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2007
From: MORTIN, LAWRENCE I.; VANPRAAGH, ANDREW; ALDER, JEFFREY; SILVERMAN, JARED
To: CUBIST PHARMACEUTICALS, INC.
Reel/Frame 020247/0056 →